Benitec Biopharma Schedules August 29th Stockholder Meeting

TL;DR

Benitec Biopharma DEF 14A filed. Special meeting Aug 29th. Vote your shares!

AI Summary

Benitec Biopharma Inc. is holding a Special Meeting of Stockholders on August 29, 2024, to vote on important matters. The company is filing its Definitive Proxy Statement (DEF 14A) on July 29, 2024, to provide shareholders with the necessary information to make informed decisions regarding the meeting.

Why It Matters

This filing informs shareholders about an upcoming meeting where their votes will determine key company decisions, impacting the future direction and potential value of Benitec Biopharma.

Risk Assessment

Risk Level: low — This is a routine proxy filing providing information for an upcoming shareholder meeting, not indicating immediate financial distress or significant operational changes.

Key Numbers

• August 29, 2024 — Special Meeting Date (Date for shareholders to vote on company matters.)
• July 29, 2024 — Filing Date (Date the proxy statement was submitted to the SEC.)

Key Players & Entities

• Benitec Biopharma Inc. (company) — Registrant
• August 29, 2024 (date) — Special Meeting Date
• July 29, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $1.93 — of Common Stock at an exercise price of $1.93 per share, (ii) Pre-Funded Warrants exe
• $0.0001 — of Common Stock at an exercise price of $0.0001 per share and (iii) Common Warrants exe
• $3.86 — of Common Stock at an exercise price of $3.86 per share, subject to the limitations o
• $3 — of Common Stock at an exercise price of $3.86, subject to the limitations on benef
• $0.0017 — of Common Stock at an exercise price of $0.0017 per share, subject to the limitations o

Filing Documents

• d874404ddef14a.htm (DEF 14A) — 312KB
• g874404dsp00a.jpg (GRAPHIC) — 3KB
• g874404dsp00b.jpg (GRAPHIC) — 3KB
• g874404g00t14.jpg (GRAPHIC) — 85KB
• g874404g02t14.jpg (GRAPHIC) — 73KB
• g874404g02t15.jpg (GRAPHIC) — 13KB
• g874404g03t14.jpg (GRAPHIC) — 17KB
• g874404g04t14.jpg (GRAPHIC) — 10KB
• g874404g04t15.jpg (GRAPHIC) — 30KB
• g874404g05t14.jpg (GRAPHIC) — 19KB
• g874404g05t15.jpg (GRAPHIC) — 9KB
• g874404g06t14.jpg (GRAPHIC) — 17KB
• g874404g06t15.jpg (GRAPHIC) — 9KB
• g874404g07t14.jpg (GRAPHIC) — 38KB
• g874404g10t14.jpg (GRAPHIC) — 15KB
• g874404g11t14.jpg (GRAPHIC) — 64KB
• g874404g36w34.jpg (GRAPHIC) — 29KB
• g874404g59c16.jpg (GRAPHIC) — 28KB
• 0001193125-24-187599.txt ( ) — 942KB

From the Filing

DEF 14A 1 d874404ddef14a.htm DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, For Use of the Commission Only (as permitted by 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional materials Soliciting Material Pursuant to 240.14a-12 BENITEC BIOPHARMA INC. (Name of Registrant as Specified in Its Charter) Payment of filing fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. Fee paid previously with preliminary materials: Table of Contents 3940 Trust Way Hayward, California 94545 SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 29, 2024 July 29, 2024 Dear Stockholders: You are cordially invited to attend the Special Meeting of Stockholders (the Special Meeting) of Benitec Biopharma Inc. (the Company). The Special Meeting will be conducted exclusively via the Internet at a virtual audio web conference at meetnow.global/MQHSXYH on August 29, 2024, beginning at 3:00 p.m., Pacific Time. You will be able to attend the Special Meeting and vote and submit questions during the Special Meeting by visiting the Special Meeting website. We believe that a virtual stockholder meeting provides greater access to those who may want to attend and therefore have chosen this over an in-person meeting. The Special Meeting is being held to seek the approval of the Companys stockholders of (i) the potential issuance of shares of common stock issuable upon exercise of certain warrants for purposes of complying with Nasdaq Listing Rule 5635(b), and (ii) an amendment to the Companys 2020 Equity and Incentive Compensation Plan previously approved by the Companys Board of Directors. The Proxy Statement describing the matters to be acted upon at the Special Meeting in more detail is contained in the following pages. Stockholders are also entitled to vote on any other matters that properly come before the Special Meeting. Your vote is important. Enclosed is a proxy that will entitle you to vote your shares on the matters to be considered at the Special Meeting, even if you are unable to attend the virtual meeting online. Regardless of the number of shares you own, please be sure you are represented at the Special Meeting either by attending virtually, voting on the Internet or by telephone, or returning a signed proxy card as soon as possible. On behalf of Benitec Biopharma Inc., I thank you for your ongoing interest and investment in our Company. Sincerely, Dr. Jerel Banks Chief Executive Officer and Chairman of the Board of Directors Table of Contents NOTICE OF SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 29, 2024 To Our Stockholders: Notice is hereby given that the Special Meeting (the Special Meeting) of Benitec Biopharma Inc. (the Company) will be held virtually on August 29, 2024, at 3:00 p.m., Pacific Time. The Special Meeting can be accessed by visiting meetnow.global/MQHSXYH, where you will be able to listen to the meeting live, submit questions, and vote online for the following purposes: (i) To approve, for purposes of complying with Nasdaq Listing Rule 5635(b), the potential issuance of shares of common stock issuable upon exercise of certain warrants (the Nasdaq Proposal); (ii) To approve an amendment to the Companys 2020 Equity and Incentive Compensation Plan previously approved by the Companys Board of Directors (the Equity Plan Amendment Proposal); and (iii) To approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for the Nasdaq Proposal or the Equity Plan Amendment Proposal. Pursuant to the Companys Amended and Restated Bylaws, the Board of Directors has fixed the close of business on July 25, 2024 as the record date for determination of the stockholders entitled to vote at the Special Meeting and any adjournments thereof. You can ensure that your shares are voted at the Special Meeting by voting via the Internet or by completing, signing and returning the enclosed proxy card. If you do attend the Special Meeting virtually, you may then withdraw your proxy and vote your shares during the virtual meeting. In any event, you may revoke your proxy prior to the Special Meeting. Shares represented by proxies that are returned properly signed but unmarked will be voted in favor of the proposals made by the Company. YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU EXPECT TO ATTEND OUR SPECIAL MEETING VIRTUALLY, PLEASE VOTE VIA THE INTERNET, BY TELEPHONE, OR SIGN AND SUBMIT YOUR PROXY AS SOON AS POSSIBLE SO THAT YOUR SHARES CAN BE VOTED AT

View Full Filing

View this DEF 14A filing on SEC EDGAR